NUVB furnishes financial results press release for Sept 30, 2025 quarter

Rhea-AI Filing Summary

Nuvation Bio Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to this Form 8-K and, along with the related information, is furnished rather than filed under the Exchange Act and Securities Act, except as specifically incorporated by reference. The company’s Class A Common Stock (NUVB) and Redeemable Warrants (NUVB.WS) are listed on the NYSE.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001811063 0001811063 2025-11-03 2025-11-03 0001811063 us-gaap:CommonStockMember 2025-11-03 2025-11-03 0001811063 nuvb:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf11.50PerShareMember 2025-11-03 2025-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025

Nuvation Bio Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39351		85-0862255
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1500 Broadway, Suite 1401

New York, NY 10036

(Address of principal executive offices)

(332) 208-6102

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share		NUVB		The New York Stock Exchange
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share		NUVB.WS		The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On November 3, 2025, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release of Nuvation Bio Inc. dated November 3, 2025.
104		Cover Page Interactive Data File (embedded within XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 3, 2025				NUVATION BIO INC.
				By:		/s/ Philippe Sauvage
				Name:		Philippe Sauvage
				Title:		Chief Financial Officer

3

FAQ

What did NUVB announce in this 8-K?

Nuvation Bio Inc. furnished a press release announcing financial results for the quarter ended September 30, 2025.

Where can I find the detailed results for NUVB's quarter ended September 30, 2025?

They are included in Exhibit 99.1, the company’s press release furnished with this 8-K.

Is the press release considered 'filed' with the SEC?

No. The information is furnished, not filed, except if expressly incorporated by reference.

What exhibits are included with this 8-K for NUVB?

Exhibit 99.1 (press release dated November 3, 2025) and Exhibit 104 (Cover Page Interactive Data File).

Which exchanges list NUVB securities?

The NYSE lists Class A Common Stock (NUVB) and Redeemable Warrants (NUVB.WS).

What is the earliest event date in this 8-K?

The date of the earliest event reported is November 3, 2025.